Converged, Combinedand Recommitted

Healthcare Technology Management was a publication created to provide practical ideas and solutions regarding the management, procurement, service and support of healthcare technology. The magazine is today reborn as a section of Clinical Innovation + Technology—you're looking at it—and our commitment to the development of the healthcare technology manager remains as strong as ever.

With all the interdepartmental convergence and collaboration occurring in today's healthcare settings, we decided to direct our content at all players and stakeholders. From directors of clinical engineering to CTOs, from administrators of clinical departments to VPs and directors of technology and medical informatics, the technology management circle is wide and expanding and certainly overlapping. Healthcare reform is sure to accelerate this tech-centric amassing.

Meanwhile, the trending convergence of IT and healthcare technology management as disciplines and departments—speeding through large academic medical institutions and gaining steam in smaller community systems—made HTM a natural fit in the development of Clinical Innovation + Technology.

This inaugural section tips you off to the kinds of stories we'll present in this space. Integrating medical devices with the EMR. Mining computerized maintenance management systems for operational intel. Looking to the cloud for disaster preparedness. On deck for next month:  Alarm management, technology acquisition and managing home-health equipment.

We hope you'll continue to find our content useful, if not indispensable. If you have a minute, feel free to drop us a line to let us know how we're doing.

Cheers,

Dave Pearson
Contributing Editor, Technology
dpearson@trimedmedia.com
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.